---
title: "Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286158548.md"
description: "Incyte Corp. (INCY) shares fell 1.19% to $99.13 on Tuesday, ending a two-day winning streak, while the Dow Jones rose 0.11% and the S&P 500 fell 0.16%. The stock is 11.72% below its 52-week high of $112.29. In comparison, competitors like Alnylam Pharmaceuticals (ALNY) rose 2.52%, while Bio-Techne (TECH) remained unchanged and BioMarin Pharmaceutical (BMRN) increased by 0.57%. Trading volume was 1.6 million, surpassing the 50-day average of 1.5 million."
datetime: "2026-05-12T21:07:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286158548.md)
  - [en](https://longbridge.com/en/news/286158548.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286158548.md)
---

# Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Incyte Corp. (INCY) slid 1.19% to $99.13 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.11% to 49,760.56 and the S&P 500 Index falling 0.16% to 7,400.96.

The stock's fall snapped a two-day winning streak.

Incyte Corp. closed 11.72% short of its 52-week high of $112.29, which the company achieved on January 7th.

The stock underperformed when compared to some of its competitors Tuesday, as Alnylam Pharmaceuticals Inc. (ALNY) rose 2.52% to $292.03, Bio-Techne Corp. (TECH) remained unchanged, and BioMarin Pharmaceutical Inc. (BMRN) rose 0.57% to $52.88.

Trading volume (1.6 M) eclipsed its 50-day average volume of 1.5 M.

Data source: Dow Jones Market Data, FactSet. Data compiled May 12, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-12-26 1707ET

### Related Stocks

- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [TECH.US](https://longbridge.com/en/quote/TECH.US.md)
- [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md)

## Related News & Research

- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study | DWTX Stock News](https://longbridge.com/en/news/286772955.md)
- [Sanofi says rare lung disease drug outperforms standard care in trial](https://longbridge.com/en/news/286810610.md)